MY194199A - A composition for the treatment of autoimmune diseases - Google Patents

A composition for the treatment of autoimmune diseases

Info

Publication number
MY194199A
MY194199A MYPI2020004121A MYPI2020004121A MY194199A MY 194199 A MY194199 A MY 194199A MY PI2020004121 A MYPI2020004121 A MY PI2020004121A MY PI2020004121 A MYPI2020004121 A MY PI2020004121A MY 194199 A MY194199 A MY 194199A
Authority
MY
Malaysia
Prior art keywords
optionally substituted
group
cycloalkyl
autoimmune diseases
compound
Prior art date
Application number
MYPI2020004121A
Inventor
Tiong Chia Yeo
Nyuk Fong Kon
Mejin Michele
Anak Ngikoh @ Nyikoh Barbara
Lau Sei Kung Gilbert
Farhan Darin Bin Azri Mohammad
Anak Ujang Jorim
Chang May Fung Melissa
Original Assignee
The Government Of The State Of Sarawak Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The State Of Sarawak Malaysia filed Critical The Government Of The State Of Sarawak Malaysia
Priority to MYPI2020004121A priority Critical patent/MY194199A/en
Priority to PCT/MY2021/050041 priority patent/WO2022035308A1/en
Publication of MY194199A publication Critical patent/MY194199A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of a compound in the manufacture of a medicament for treating autoimmune diseases by inhibiting Tumor Necrosis Factor with reduced risk of fungal infections, wherein the compound is of Formula (I), wherein: each R?-R?? is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted cycloalkylalkyl, optionally substituted arylacyl, optionally substituted cycloalkylacyl and a C-1 linked saccharide; X is OR? or NR?R??; R?? and R?? are each independently hydrogen or, OR? and R??, and/or OR? and R?? together form a methylenedioxy group; and Y is selected from the group consisting of optionally substituted phenyl, optionally substituted benzyl, optionally substituted benzoyl, optionally substituted C?-C? cycloalkyl, optionally substituted CH?-(C?-C? cycloalkyl), optionally substituted 5-6 membered heterocyclyl and optionally substituted CH?-(5-6 membered heterocyclyl). The medicament further comprises Uncaria gambir incorporated as extract, enriched fraction or its bioactive compounds, to provide anesthetic or analgesic effect.
MYPI2020004121A 2020-08-11 2020-08-11 A composition for the treatment of autoimmune diseases MY194199A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MYPI2020004121A MY194199A (en) 2020-08-11 2020-08-11 A composition for the treatment of autoimmune diseases
PCT/MY2021/050041 WO2022035308A1 (en) 2020-08-11 2021-05-28 A composition for the treatment of autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2020004121A MY194199A (en) 2020-08-11 2020-08-11 A composition for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
MY194199A true MY194199A (en) 2022-11-21

Family

ID=80247255

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020004121A MY194199A (en) 2020-08-11 2020-08-11 A composition for the treatment of autoimmune diseases

Country Status (2)

Country Link
MY (1) MY194199A (en)
WO (1) WO2022035308A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ866500A0 (en) * 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
EP1693059A1 (en) * 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
WO2013016658A1 (en) * 2011-07-27 2013-01-31 The Ohio State University Research Foundation Silvestrol, silvestrol analogs and uses thereof

Also Published As

Publication number Publication date
WO2022035308A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
MX2023000798A (en) Functionalized peptides as antiviral agents.
MX2023009222A (en) Tricyclic-amido-bicyclic prmt5 inhibitors.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
SA521430792B1 (en) Nitrile-containing antiviral compounds
MX2023005984A (en) Novel spiropyrrolidine derived antiviral agents.
MX2023005983A (en) Novel spiropyrrolidine derived antiviral agents.
UA86614C2 (en) Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine
CO2026005655A2 (en) Pan-kras inhibitor and its use in medicines
MX2023001756A (en) Functionalized peptides as antiviral agents.
EA201071040A1 (en) NEW DERIVATIVES 1-BENZYL-3-HYDROXYMETHYLINDASOL AND THEIR APPLICATION IN THE TREATMENT OF DISEASES CAUSED BY EXPRESSION OF MCP-1, CX3CR1 And P40
TR201802944T4 (en) DERIVATIVES OF AZAINDAZOL OR DIAZAINDAZOL
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CU20110217A7 (en) AMINO-PROPIONIC DERIVATIVES REPLACED AS NEPRILISINE INHIBITORS
EA201201159A1 (en) DETERATED PYRROPOLYMIDININE COMPOUNDS AS CDK4 / 6 INHIBITORS
EA202092168A1 (en) APPLICATION OF FAVIPIRAVIR IN THE TREATMENT OF CORONAVIRUS INFECTION
RU2013121788A (en) HIV REPLICATION INHIBITORS
MX340965B (en) Combinations for the treatment of diseases involving cell proliferation.
RU2012101947A (en) METHODS FOR TREATING AND PREVENTING FATIGUE
PH12022551523A1 (en) Cyclic compounds and methods of using same
MX2022015554A (en) Small molecule modulators of il-17.
MY199779A (en) Pyrrolopyrimidine compound and use thereof
MX2022003617A (en) HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR IMPROVEMENT OF CANCER.
PY2132400A (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING HIF2a ACTIVITY AND THEIR METHODS OF USE
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2025005357A (en) Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof